Announcements Trials
Browse Landscape

Phase

Phase 2 75Phase 3 70Phase 1 15Phase 1/2 8Phase 4 3Phase 2/3 3Phase NA 2Phase EARLY_PHASE1 1

Status

Unknown 8Completed 3Active not recruiting 3Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Breast 1

Conditions

Stomach Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Breast Neoplasms 1

Interventions

Cisplatin 22Fluorouracil 21Radiotherapy 18Gemcitabine 17Docetaxel 16Oxaliplatin 15Paclitaxel 14Carboplatin 13Capecitabine 13Bevacizumab 13Leucovorin 11Cyclophosphamide 11Irinotecan 10Drug Therapy 10Cytarabine 9Saline Solution 7Magnetic Resonance Spectroscopy 7Letrozole 7Dexamethasone 7Rituximab 6Nivolumab 6Methotrexate 6Exercise 6Etoposide 6Electroporation 6Doxorubicin 6pembrolizumab 5Pemetrexed 5Metformin 5Melphalan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Completed × Epirubicin × Clear all
NCT01779206 2025-04-08

ADAPT

West German Study Group

Phase 2/3 Completed
4,936 enrolled
Breast

Breast Neoplasms

NCT01216644 2019-06-19

5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer

Krankenhaus Nordwest

Phase 2/3 Completed
716 enrolled
Gastrointestinal

Pathologic Complete Response, Stomach Neoplasms

NCT00960284 2012-01-13

PACT-7

IRCCS San Raffaele

Phase 2/3 Completed
102 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡